{"id":"biological-etanercept-and-its-biosimilars","safety":{"commonSideEffects":[{"rate":"10–26","effect":"Injection site reactions"},{"rate":"5–10","effect":"Upper respiratory tract infections"},{"rate":"5–10","effect":"Headache"},{"rate":"1–3","effect":"Serious infections (including tuberculosis)"},{"rate":"<1","effect":"Demyelinating disease"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Etanercept consists of the extracellular ligand-binding domain of the human TNF receptor p75 fused to the Fc portion of human IgG1. It acts as a soluble TNF receptor that competitively binds circulating TNF-α and TNF-β, preventing their interaction with cell-surface TNF receptors and thereby suppressing the inflammatory cascade. This mechanism reduces pathogenic immune activation in autoimmune and inflammatory conditions.","oneSentence":"Etanercept is a TNF receptor fusion protein that binds and neutralizes tumor necrosis factor (TNF), a key inflammatory cytokine driving immune-mediated diseases.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:28:35.942Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Psoriatic arthritis"},{"name":"Polyarticular juvenile idiopathic arthritis"},{"name":"Plaque psoriasis"},{"name":"Crohn's disease"}]},"trialDetails":[{"nctId":"NCT05164198","phase":"PHASE4","title":"REduCed Dose of TNFi in Patients With Ankylosing SpondyliTis (RECAST)","status":"UNKNOWN","sponsor":"Hanyang University Seoul Hospital","startDate":"2022-01-15","conditions":"Ankylosing Spondylitis, Axial Spondyloarthritis","enrollment":448}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Enbrel","Eucept","Etalace"],"phase":"marketed","status":"active","brandName":"Biological: Etanercept and its biosimilars","genericName":"Biological: Etanercept and its biosimilars","companyName":"Hanyang University Seoul Hospital","companyId":"hanyang-university-seoul-hospital","modality":"Biologic","firstApprovalDate":"","aiSummary":"Etanercept is a TNF receptor fusion protein that binds and neutralizes tumor necrosis factor (TNF), a key inflammatory cytokine driving immune-mediated diseases. Used for Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}